Photo

Photo detail

Stories this photo appears in:

Allergan Gets China OK for Eye Device

Allergan PLC received Chinese regulatory approval for Ozurdex, an eye implant designed to treat adults with macular edema following retinal vein occlusion—an eye stroke.

Tease photo

Botox Approved for Forehead Lines

Allergan PLC received Food and Drug Administration approval to use Botox to temporarily reduce moderate to severe forehead lines.

Tease photo

Allergan Gets Korean Market OK

Allergan PLC received Korean Ministry of Food and Drug Safety approval for Belkyra, an injection that aims to reduce double chin by destroying fat cells under the chin.

Tease photo

Allergan Cuts 109 Jobs

Allergan PLC laid off 109 employees at its Irvine campus, according to a recent report to the state Employment Development Department.

Tease photo

$2.47B Allergan Buy Adds in Irvine

Allergan PLC announced that it will buy Pleasanton-based Zeltiq Aesthetics Inc.’s CoolSculpting System for $2.47 billion, or $56.50 per share, in a transaction that’s expected to be completed in the second half of 2017.

Tease photo

Allergan Study: 1,563 OC Jobs, $307M Payroll

Allergan Plc’s local operations provide 1,563 jobs here with a combined payroll of about $307 million, based on the company’s average salary statewide, an economic impact study said.

Tease photo

Allergan to Buy Glaucoma Co. for $95M

Allergan Plc plans to buy ForSight Vision5 for $95 million and milestone payments.

Tease photo

Allergan Realigns Businesses

Allergan PLC has reorganized its business segments as it prepares to divest its generic drug unit.

Tease photo

Allergan Name to Go in $155B Pfizer Deal

Allergan PLC and Pfizer Inc. will merge in a deal worth about $155 billion.

Tease photo

Allergan Shares Up on Pfizer Talks

Shares in Allergan PLC rose about 9% in morning trading after the drug maker and potential partner Pfizer Inc. confirmed the two companies were discussing a merger.

Tease photo

Allergan Wraps $300M AqueSys Deal

Allergan PLC finalized its purchase of Aliso Viejo-based AqueSys Inc. for $300 million plus milestone payments.

Tease photo

Allergan Shares Briefly Halted

Trading of shares in Allergan PLC, whose Botox and eye drug hubs are in Irvine, was briefly halted today and are down in midday trading on news involving rival Valeant Pharmaceuticals International Inc.

Tease photo

Allergan’s Kythera to Lay Off 117

Kythera Biopharmaceuticals Inc. is cutting 117 workers – or more than half its workforce – after its acquisition earlier this month by Dublin, Ireland-based drug maker Allergan PLC in an all-cash deal valued at some $2.1 billion, according to a state filing.

Tease photo

Allergan, Humana Teaming Up on Research

Allergan PLC, whose eye drug hub is located in Irvine, said today that it will collaborate with Louisville, Ky.-based insurer Humana Inc. on research that will include glaucoma and other eye diseases.

Tease photo

FDA Clears Allergan’s Juvéderm Filler for Lips

The U.S. Food and Drug Administration today approved Allergan PLC’s Juvéderm Ultra XC for lip augmentation in adults who are at least 21 years old.

Tease photo

Allergan in $300M Deal for Aliso Viejo Eye Device Maker

Allergan PLC, which has its eye drug hub in Irvine, said today that it is buying Aliso Viejo-based AqueSys Inc. for $300 million up front, with the potential for milestone payments.

Tease photo

Allergan in $40B Generics Deal

Allergan PLC said today that it will sell its generic drug business for $40.5 billion in cash and stock to Teva Pharmaceutical Industries Ltd.

Tease photo

Allergan Buys Dry Eye Company

Allergan PLC, whose eye drug hub is in Irvine, said today that it will buy Oculeve Inc. for $125 million plus milestone payments.

Tease photo

Allergan Adds to Aesthetics Line

Allergan Plc will buy Westlake Village, Calif.-based Kythera Biopharmaceuticals Inc. for cash and stock valued at $2.1 billion.

Tease photo

Allergan Laying Off 577 in Irvine

Allergan Inc., now a business unit of drugmaker Actavis PLC, will lay off 577 workers in Irvine, according to a state filing.

Tease photo

Allergan Laying Off 577 in Irvine

Allergan Inc., now a business unit of drugmaker Actavis PLC, will lay off 577 workers in Irvine, according to a state filing.

Tease photo

Allergan Ends Legal Battle With Ackman, Valeant

Allergan Inc., the Irvine drug maker that is now part of Dublin-based Actavis Plc., has ended its court fight with Canada-based Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman’s New York City-based Pershing Square Capital Management LP.

Tease photo

Actavis Wraps Up Allergan Buy; Pyott Passes on Board Seat

Actavis PLC said today that it completed its acquisition of Irvine-based drugmaker Allergan Inc., currently valued at about $72.5 billion.

Tease photo

Allergan Shareholders Vote for Actavis Deal

A majority of Irvine-based Allergan Inc.’s shareholders voted this morning to accept a takeover bid currently valued at $70.7 billion from Actavis PLC.

Tease photo

Allergan Beats Analysts' Expectations

Irvine-based Allergan Inc. Wednesday reported mixed fourth-quarter financial results.

Tease photo

Allergan Sets Meeting on Actavis Deal

Irvine-based Allergan Inc. has set a March 10 special meeting to get shareholder approval of its acquisition by Actavis PLC in a cash-and-stock deal currently valued at about $70 billion.

Tease photo

Allergan, Actavis Deal Advances

Irvine-based Allergan Inc. and Dublin-based Actavis Plc said the U.S. Federal Trade Commission granted early termination of a federal regulatory waiting period and set a ‘shareholder-of-record’ date for the $68 billion acquisition of Allergan by Actavis.

Tease photo

Valeant, Ackman Cash Out of Allergan

Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman’s Pershing Square Capital Management LP have slashed their stake in Irvine-based Allergan Inc. after losing a bidding war to Actavis PLC.

Tease photo

Allergan, Actavis in “Advanced Talks”

Irvine-based drug maker Allergan Inc. is in advanced negotiations with potential “white knight” suitor Actavis PLC, according to a Bloomberg report Wednesday.

Tease photo

Allergan, Actavis in “Advanced Talks”

Irvine-based drug maker Allergan Inc. is in advanced negotiations with potential “white knight” suitor Actavis PLC, according to a Bloomberg report.

Tease photo

Allergan Said in Talks with Actavis

Irvine-based drug maker Allergan Inc. is in active talks with New Jersey-based Actavis PLC about a deal, sources familiar with the situation told Bloomberg today.

Tease photo

Pershing Square, Valeant Can Vote Allergan Shares

Valeant Pharmaceuticals International, Inc. in Quebec and Pershing Square Capital Management, L.P. in New York, can vote their shares of Allergan Inc. at the Dec. 18 shareholder meeting of the Irvine-based drug maker, according to a ruling issued today.

Tease photo

Allergan Approached by Actavis, Reuters Says

A regulatory filing by Irvine-based Allergan Inc. today confirmed that is has been approached by another company about a potential transaction.

Tease photo

Valeant Might Up Bid; Allergan Beats the Street

Valeant Pharmaceuticals International Inc. said today it would be willing to raise its hostile takeover bid for Irvine-based Allergan Inc. to $200 a share.

Tease photo

Allergan Laying Off 40 in Carlsbad

Irvine-based drug maker Allergan Inc. filed papers with state officials saying it will lay off 40 workers in Carlsbad, effective Nov. 28, according to a Worker Adjustment and Retraining Notification notice filed with the state Employment Development Department.

Tease photo

Allergan Hikes Q3 Expectations

Irvine-based Allergan Inc. said today that it expects to report a third-quarter profit more than 20% higher than previously expected.

Tease photo

Report Says Actavis to Make New Allergan Pitch

Irvine-based Allergan Inc. will be approached again about being bought by Actavis PLC, according to a Reuters report today.

Tease photo

Ackman Threatens Suit on Allergan Buy

Activist investor Bill Ackman has threatened to sue Allergan Inc. if the Irvine-based drug maker goes ahead with an acquisition of Salix Pharmaceuticals Ltd. in a deal that doesn’t require a vote of Allergan shareholders.

Tease photo

WSJ: Allergan in Advanced Talks for Potential Salix Deal

Irvine-based Allergan Inc. is in advanced talks to buy Salix Pharmaceuticals Ltd. after turning down a buyout offer from Actavis PLC, according to a report today in the Wall Street Journal.

Tease photo

Allergan to Cut 129 Irvine Jobs

Irvine-based Allergan Inc. has filed papers with state officials saying it will lay off 129 employees.

Tease photo

Allergan to Cut 129 Irvine Jobs

Irvine-based Allergan Inc. has filed papers with state officials saying it will lay off 129 employees.

Tease photo

Allergan Buzz: Jazz Phamarceuticals a Buy?

Shares of Jazz Pharmaceuticals PLC rose today after an industry website said it would likely be the most viable deal target for Irvine-based Allergan Inc.

Tease photo

Allergan Answers Valeant, Pershing Square

Irvine-based Allergan Inc. said today that it filed an answer in U.S. District Court to a countersuit filed by Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman’s Pershing Square Capital Management.

Tease photo

Trial Date on Special Allergan Meeting Set

A Delaware Chancery Court judge today set a Oct. 6 date for a trial over the timing of a special meeting of Irvine-based Allergan Inc. shareholders.

Tease photo

Allergan Confirms Shareholder Meeting Request

Irvine-based Allergan Inc. has confirmed it received written requests from shareholders to call a special meeting requested by activist investor Bill Ackman’s Pershing Square Capital Management LP.

Tease photo

CNBC: Threshold Met for Special Meeting on Allergan

Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman’s Pershing Square Capital Management LP will submit a request today to Irvine-based Allergan Inc. calling for a special meeting of shareholders, according to reports.

Tease photo

Does Dual Dip Point to Diminished Prospects for Allergan Deal?

HEALTHCARE: Valeant bid valued just above target’s market value

Investor sentiment appears to be quietly moving away from the increasingly noisy takeover attempt of Irvine-based Allergan Inc.

Tease photo

Allergan Raises Bar on Raiders With Cost Cuts, Pledge on Profits

Allergan Inc.’s promise of cost cuts and higher profits might have put the company out of its hostile suitors’ reach.

Tease photo

Allergan to Cut 1,500 Jobs

Allergan Inc. said it will cut about 1,500 jobs over the remainder of this year as part of a restructuring plan to save about $475 million next year.

Tease photo

Allergan Rebuffs Valeant's Latest Move

Valeant Pharmaceuticals International Inc. has filed a pre-merger notification with the U.S. Federal Trade Commission in its pursuit of Irvine-based Allergan Inc.

Tease photo

FDA Approves One Allergan Drug, Delays Another

Irvine-based Allergan Inc. said today that the Food and Drug Administration delayed approving its new acute migraine headache drug and separately approved a drug for treating diabetic macular edema.

Tease photo

Reports: Paulson & Co. Buys Allergan Shares, Backs Valeant Offer

Hedge fund Paulson & Co. has acquired more than 6 million shares of Irvine-based drug maker Allergan Inc.’s common stock and expressed support for Valeant Pharmaceuticals International Inc.’s hostile bid for the company, according to recent reports.

Tease photo

Allergan to Shareholders: Reject Valeant’s Latest Bid

Allergan Inc. has urged its shareholders to reject the latest advance from hostile suitor Valeant Pharmaceuticals International Inc.

Tease photo

Ackman Says He'll Seek to Replace Allergan Directors

Activist investor Bill Ackman said today that he and his Pershing Square Capital Management LP will call for a special shareholders’ meeting of Allergan Inc. in order to remove six of its directors—the latest in the ongoing hostile takeover effort by Valeant Pharmaceuticals International Inc.

Tease photo

Valeant, Ackman Hike Allergan Bid Again

Valeant Pharmaceuticals International Inc. today added more cash to its hostile takeover bid for Irvine-based Allergan Inc.

Tease photo

Valeant, Ackman Hike Allergan Bid Again

Valeant Pharmaceuticals International Inc. today added more cash to its hostile takeover bid for Irvine-based Allergan Inc.

Tease photo

Valeant Raises Bid for Allergan

Valeant Pharmaceuticals International Inc. has added more cash to its hostile bid for Irvine-based drug maker Allergan Inc., raising the total offer to about $50 billion.

Tease photo

Investors: Valeant Must Hike Allergan Bid

Valeant Pharmaceuticals International Inc. should raise its unsolicited offer to buy Irvine-based Allergan Inc. to roughly $53.5 billion to $59.5 billion or $180 to $200 a share, according to an investor survey released today by JP Morgan.

Tease photo

Analyst: Allergan Likely to Stand Alone

Allergan Inc. is likely to remain a standalone company, according to recent report by a veteran analyst.

Tease photo

Analyst: Allergan Likely to Stand Alone

Allergan Inc. is likely to remain a standalone company, according to recent report by a veteran analyst.

Tease photo

Valeant to Hike Allergan Bid

Valeant Pharmaceuticals International Inc. said today that it will put in an “improved offer” to buy Irvine-based Allergan Inc.

Tease photo

Allergan Beats on Q1, Lifts Guidance amid Valeant Bid

Irvine-based Allergan Inc. on Wednesday reported first-quarter profit and revenue that surpassed analysts’ expectations and hiked its full-year guidance.

Tease photo

Allergan Beats on Q1, Lifts Guidance amid Valeant Bid

Irvine-based Allergan Inc. today reported first-quarter profit and revenue that surpassed analysts’ expectations and hiked its full-year guidance.

Tease photo

Allergan Eyeing Shire?

Irvine-based drug maker Allergan Inc. is considering a bid for Shire plc as a possible way to thwart a hostile takeover by Valeant Pharmaceuticals International Inc., according to reports.

Tease photo

Allergan Eyeing Shire?

Irvine-based drug maker Allergan Inc. is considering a bid for Shire plc as a possible way to thwart a hostile takeover by Valeant Pharmaceuticals International Inc., according to reports.

Tease photo

Allergan Adopts Poison Pill Defense

Irvine-based drug maker Allergan Inc. has adopted a stockholder rights plan in response to a hostile takeover bid by Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman.

Tease photo

Valeant Sets Bid at $47B

Valeant Pharmaceuticals Inc., an unsolicited suitor of Irvine-based drug maker Allergan Inc., has set its bid for the acquisition at $47 billion.

Tease photo

Allergan Acquires Dermal Filler Candidate

Irvine-based Allergan Inc. acquired a dermal filler candidate from Menlo Park-based incubator TauTona Group.

Tease photo

Allergan Acquires Dermal Filler Candidate

Irvine-based Allergan Inc. said today that it acquired a dermal filler candidate from Menlo Park-based incubator TauTona Group.

Tease photo

Allergan Beats Estimates, Issues Conservative Guidance

Irvine-based Allergan Inc. today reported fourth-quarter financial results that surpassed expectations and issued a cautious outlook for the current quarter.

Tease photo

Allergan Names New Director

Irvine-based Allergan Inc. said today in a federal filing that it has added a seat on its board of directors and appointed a former Genzyme Corp. chief executive to the post, effective Jan. 24.

Tease photo

Allergan Names New Director

Irvine-based Allergan Inc. said today in a federal filing that it has added a seat on its board of directors and appointed a former Genzyme Corp. chief executive to the post, effective Jan. 24.

Tease photo

Allergan Selling Obesity Intervention Business

Irvine-based Allergan Inc. said today that it has a deal to sell its Lap-Band and Orbera weight loss devices to Austin-based Apollo Endosurgery Inc. for $75 million in cash and other considerations.

Tease photo

Allergan Beats for Q3, Tamps Down Q4 Outlook

Irvine-based drug maker Allergan Inc. today reported third-quarter results that beat analysts’ estimates and issued guidance for the current quarter.

Tease photo

Botox Boosts Allergan’s Q2 Performance

Irvine-based Allergan Inc. today posted second-quarter financial results that exceeded analysts’ forecasts and raised the lower end of its full-year forecast.

Tease photo

Allergan Shares Fall on Generic Competition Concerns

Irvine-based drug maker Allergan Inc.’s shares fell sharply today after analysts downgraded the company over possible generic competition for its Restasis dry-eye treatment.

Tease photo

Allergan Tumbles on Drug Delays

Shares of Irvine-based drug maker Allergan Inc. fell in early trading today after it lowered its full-year financial forecast.

Tease photo